Johnson & Johnson vs. Prelude Therapeutics Incorporated
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| JNJ | PRLD | |
|---|---|---|
| Market Cap | $644.82 billion | $388.64 million |
| Revenue (TTM) | $97.93 billion | $22.42 million |
| Net Income (TTM) | $21.04 billion | $-60,488,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | PRLD | |
|---|---|---|
| P/E Ratio | 30.71 | — |
| Price / Book | 7.59 | 2.91 |
| Price / Sales | 6.58 | 17.33 |
JNJ and PRLD split the valuation factors evenly.
Profitability
| JNJ | PRLD | |
|---|---|---|
| Net Margin | 21.48% | -269.75% |
| Return on Equity | 24.76% | -45.23% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | PRLD | |
|---|---|---|
| Dividend Yield | 2.02% | — |
| Payout Ratio | 62.18 | — |
JNJ and PRLD split the dividend factors evenly.
Risk & Sentiment
| JNJ | PRLD | |
|---|---|---|
| Short Interest | 0.67% | 0.01% |
PRLD leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, PRLD overview, PRLD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.